Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II ANX776 study in healthy volunteers and patients with glaucoma, age-related macular degeneration, or optic neuritis
2016-002531-15Phase 2Completed
- Sponsor
- UCL Comprehensive Clinical Trials Unit
- Start
- Sep 2016
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of ANX776 in Glaucoma, age-related macular degeneration (AMD) and optic neuritis (ON) (4 arms), sponsored by UCL Comprehensive Clinical Trials Unit. Primary endpoint: DARC count at 4 hours post injection. Started Sep 2016; status: completed.
02
Drugs
ANX776
03
Conditions
Glaucomaage-related macular degeneration (AMD)optic neuritis (ON)
Beyond the preview
Go deeper on 2016-002531-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-002531-15.